US Patent 12,194,008: Metoclopramide Nasal Spray Patent Scope and Competitive Landscape

U.S. Patent 12,194,008 covers a treatment method for gastroparesis using intranasal metoclopramide at a daily dose of approximately 30 mg to 60 mg in a composition containing at least approximately 10 mM citrate. The broadest claim is a combination claim. An accused product or treatment must satisfy every limitation of claim 1, including the route of administration, dose range, citrate concentration, and therapeutic purpose.

The patent does not, based on the supplied claims, broadly cover all intranasal metoclopramide products, all metoclopramide compositions, or all treatments for gastroparesis. Its commercial significance is concentrated in higher-dose intranasal metoclopramide regimens, particularly nasal sprays using citrate-containing formulations.

What patents protect intranasal metoclopramide for gastroparesis?

The asserted claim set protects a method of treating gastroparesis rather than a composition or device in isolation.

Claim element	Scope of protection
Active ingredient	Metoclopramide or a pharmaceutically acceptable salt
Administration route	Intranasal
Disease	Gastroparesis
Daily dose	About 30 mg to about 60 mg
Formulation requirement	Citrate concentration of at least about 10 mM
Therapeutic result	Administration must be effective to treat gastroparesis
Patient	Human patients are covered by claim 13, but claim 1 is not expressly limited to humans
Dosage form	Intranasal spray is covered by claim 2 and its dependents

Claim 1 is the principal commercial barrier. Claims 2 through 17 add narrower formulation, dosing, preservative, buffer, patient, and symptom limitations.

The claim does not expressly require a particular metoclopramide concentration per spray, bottle size, delivery device, particle size, spray volume, manufacturing process, or brand name. Those characteristics could still matter under other claims in the patent family or under separate patents.

How does claim 1 define infringement risk?

Literal infringement of claim 1 requires a product or treatment protocol with all of the following characteristics:

A patient has gastroparesis.
Metoclopramide, or a pharmaceutically acceptable salt, is administered intranasally.
The administration delivers a daily dose of about 30 mg to about 60 mg.
The composition contains citrate at a concentration of at least about 10 mM.
The administration is effective to treat gastroparesis.

The claim is drafted as a method-of-treatment claim. Liability generally turns on performance of the claimed steps, not merely on possession of a nasal formulation. A manufacturer could face inducement or contributory infringement allegations if it supplies a product with instructions or characteristics that encourage the claimed use, even where the manufacturer does not administer the product itself. The relevant statutory framework includes 35 U.S.C. §§ 271(b) and 271(c).

The phrase “about” creates a numerical boundary dispute. Courts would evaluate the intrinsic record, specification, prosecution history, technical meaning, and potentially expert evidence to determine how far the dose and citrate ranges extend. A product at 29 mg or 61 mg is not automatically outside the claim.

What formulations are protected by US Patent 12,194,008?

The patent protects a broad formulation class only when the composition is used in the claimed intranasal gastroparesis treatment.

Citrate requirement

Citrate is mandatory in claim 1. The concentration must be at least about 10 mM. A formulation using phosphate, acetate, borate, or another buffer without citrate would not literally satisfy claim 1, although other claims or patents could create separate risks.

Claim 9 narrows the buffer to sodium citrate. Claim 8 contains a long Markush list of buffer systems, including citrate, citrate-phosphate systems, acetate, phosphate, borate, succinate, maleate, MOPS, HEPES, PIPES, TES, and other biological buffers. Claim 8 is dependent on claim 1, so the composition must still contain citrate at the threshold specified in claim 1.

The drafting creates a potential construction issue: claim 8 lists citrate-based and non-citrate buffers, but claim 1 independently requires citrate. The listed buffer may therefore be an additional buffer component or a buffer system that also satisfies the citrate limitation, depending on the specification and prosecution history.

Benzalkonium chloride

Claims 4 and 5 cover compositions containing benzalkonium chloride at approximately 0.005% to 0.05% w/v. These claims may be relevant to preserved multidose nasal sprays.

The preservative limitation is not required by claim 1. A formulation without benzalkonium chloride can still infringe claim 1 if the other limitations are met.

pH and osmolality

Claim 6 covers a composition with a pH above approximately 4.5. Claim 7 covers osmolality from approximately 500 mOsm/kg to approximately 1,400 mOsm/kg.

These ranges narrow the claims but may capture many practical nasal formulations. The broad osmolality range is particularly important because it extends well above physiological isotonicity. A design-around based on pH or osmolality would require reliable analytical testing and careful evaluation of the “about” language.

EDTA, sorbitol, and antioxidants

Claim 12 covers compositions containing EDTA or sorbitol. Claim 14 covers compositions substantially free of any additional antioxidant.

The antioxidant limitation is unusual because it is defined negatively. “Substantially free” may generate disputes concerning trace excipients, degradation products, formulation impurities, and whether a preservative or stabilizer is technically an antioxidant.

Which dependent claims create the principal commercial restrictions?

Claims	Added limitation	Commercial relevance
2	Intranasal spray	Targets the likely commercial dosage form
3	One, two, three, or four sprays per day	Addresses administration frequency
4-5	Benzalkonium chloride at 0.005%-0.05% w/v	Targets preserved multidose formulations
6	pH above about 4.5	Narrows formulation chemistry
7	Osmolality of about 500-1,400 mOsm/kg	Captures hyperosmotic formulations
8-9	Specified buffers, including sodium citrate	Adds formulation-specific coverage
10-11	Treatable symptoms, including emesis and nausea	Links the method to labeled or clinically recognized symptoms
12	EDTA or sorbitol	Adds excipient-specific coverage
13	Human patient	Removes nonhuman ambiguity
14	Substantially free of additional antioxidant	Negative formulation limitation
15-17	Approximately 30, 45, or 60 mg daily	Provides dose-specific fallback positions

Claims 15, 16, and 17 are important prosecution and litigation fallback claims. If a court construes the 30 mg to 60 mg range narrowly or finds a dispute at an endpoint, the patent owner may rely on the separate 30 mg, 45 mg, or 60 mg claims.

How strong is the patent estate based on the supplied claims?

The claims have moderate-to-strong product relevance but narrower legal breadth than a composition claim.

Strengths

The claims target the principal therapeutic use of intranasal metoclopramide for gastroparesis.
Claim 1 combines route, dose, disease, and formulation limitations, making it commercially aligned with a marketed nasal product.
The citrate threshold may capture a defined formulation platform rather than merely the active ingredient.
The dependent claims provide multiple formulation and dosing positions.
Claims 15 through 17 create exact-dose alternatives at 30 mg, 45 mg, and 60 mg.
Claims 2 and 3 map directly onto a spray product and common daily administration schedules.

Vulnerabilities

The claim requires proof of at least approximately 10 mM citrate.
The daily dose must fall within approximately 30 mg to 60 mg.
The claim requires intranasal administration and does not reach oral, injectable, or transdermal metoclopramide products.
“Effective to treat gastroparesis” may create questions concerning clinical evidence, labeling, and the required therapeutic result.
“About,” “substantially free,” and “effective” are potential claim-construction disputes.
Prior-art risk may arise from earlier intranasal metoclopramide disclosures, nasal formulations containing citrate, and clinical protocols using doses within the claimed range.
The claims do not, on their face, protect the nasal device, manufacturing process, analytical methods, or every formulation containing metoclopramide.

Patent validity would depend on the complete specification, priority chain, prosecution history, cited references, and any terminal-disclaimer or patent-term-adjustment information. Claim text alone cannot establish those points.

What generic entry risks exist?

A generic or follow-on entrant would face the highest risk where its product has all of these characteristics:

intranasal metoclopramide;
a labeled gastroparesis indication;
a daily regimen between approximately 30 mg and 60 mg;
citrate at or above approximately 10 mM; and
a spray presentation.

A product could reduce literal infringement exposure by changing one or more claim-critical parameters:

Potential design-around	Principal risk
Oral or injectable administration	Outside the express intranasal limitation
Daily dose below 30 mg or above 60 mg	“About” range and doctrine-of-equivalents exposure
Citrate below approximately 10 mM	Measurement and “about” disputes
Non-citrate formulation	Potentially stronger design-around, subject to other patents
Different therapeutic indication	Risk if gastroparesis use is reasonably foreseeable or encouraged
Different formulation pH or osmolality	Only avoids the narrower dependent claims
Preservative-free packaging	Avoids claims 4-5 but not claim 1
One-time or non-spray delivery	Avoids claims 2-3 but not claim 1 if intranasal administration remains

A Paragraph IV certification would be the principal Hatch-Waxman pathway for challenging listed patent claims before expiration. The certification would require a detailed noninfringement, invalidity, or unenforceability position under 21 U.S.C. § 355(j)(2)(A)(vii)(IV). A filing by an ANDA applicant could trigger patent litigation and, if timely filed, a statutory stay of approval of up to 30 months under 21 U.S.C. § 355(j)(5)(B)(iii).

What is the Orange Book status of US Patent 12,194,008?

Orange Book listing cannot be determined from the supplied claim text. The patent’s method claims could be eligible for listing if they claim an approved method of using the drug and satisfy FDA listing standards. Listing depends on the FDA’s Orange Book records, the NDA holder’s submission, and the relationship between the patent claims and the approved labeling.

An Orange Book-listed patent can affect ANDA certifications and launch timing. Listing alone does not establish validity, enforceability, or infringement.

For an intranasal metoclopramide product, the relevant regulatory records would include the approved NDA, current labeling, patent-use-code information, and the Orange Book patent table. The approved label is also central to evaluating induced infringement and whether the claimed gastroparesis use is a labeled use.

Does biosimilar risk apply to this patent?

No conventional biosimilar pathway applies. Metoclopramide is a small-molecule drug, not a biologic. Competitive entry would ordinarily proceed through an ANDA under section 505(j) or, in some circumstances, a 505(b)(2) application under section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act.

The principal competitive risks are therefore generic and hybrid-drug entry, not biosimilar substitution.

What patent litigation and settlement issues matter?

The supplied material does not identify a complaint, Paragraph IV notice, district court action, PTAB proceeding, settlement agreement, or license involving U.S. Patent 12,194,008. Those matters cannot be inferred from the claims.

If litigation occurs, the most likely disputes would concern:

Whether the accused product contains citrate at or above approximately 10 mM.
Whether the labeled or expected use delivers 30 mg to 60 mg per day.
Whether the product is intended to treat gastroparesis.
Whether “about” extends beyond the stated numerical range.
Whether earlier intranasal metoclopramide disclosures anticipate or render obvious the combination.
Whether the claims are enabled across the full buffer and excipient scope.
Whether the method claims are enforceable against a manufacturer whose label includes a narrower indication or dosing regimen.

A settlement could permit entry before patent expiry through a licensed launch date, authorized generic arrangement, supply agreement, or label carve-out. No such agreement is established by the supplied claims.

How does this patent compare with typical formulation and method patents?

Patent category	Protection focus	Relevance to US 12,194,008
Active-ingredient patent	Chemical compound	Metoclopramide is an established active ingredient; this patent does not claim its basic composition
Composition patent	Formulation and excipients	The supplied claims use formulation limitations, but only within a treatment method
Device patent	Spray pump, actuator, container, or delivery control	No device limitation appears in claims 1-17
Manufacturing patent	Preparation, filling, sterilization, or packaging	No manufacturing step appears in the claims
Method-of-treatment patent	Route, dose, disease, and clinical use	This is the primary category
Label-use patent	Approved indication or patient subgroup	Claims 10-11 add symptom-specific treatment scope
Biologic patent	Reference product and biosimilar exclusivity	Not applicable to metoclopramide

The patent is commercially meaningful where the product, label, and formulation align. It is less effective against products that use a different route, different active ingredient, materially different dose, or non-citrate formulation.

Key Takeaways

Claim 1 requires intranasal metoclopramide, gastroparesis treatment, a daily dose of approximately 30 mg to 60 mg, and at least approximately 10 mM citrate.
The patent is primarily a method-of-treatment patent, not a standalone nasal-composition or spray-device patent.
Claims 2 and 3 target nasal spray products and one-to-four-spray daily regimens.
Claims 4-9 and 12-14 add formulation restrictions involving benzalkonium chloride, pH, osmolality, buffers, EDTA, sorbitol, human use, and antioxidants.
Claims 15-17 provide exact-dose fallback positions at approximately 30 mg, 45 mg, and 60 mg.
Generic risk is highest for a citrate-containing intranasal metoclopramide spray labeled for gastroparesis at the claimed daily dose.
Biosimilar risk does not apply because metoclopramide is a small-molecule drug.
Orange Book listing, patent expiration, priority, licensing, litigation, and settlement status cannot be established from the supplied claims alone.

FAQs

Can an oral metoclopramide generic infringe US Patent 12,194,008?

Not literally under the supplied claims, because each claim requires intranasal administration. Oral use could still implicate other patents, regulatory theories, or indirect-infringement arguments only if the relevant legal and factual elements are established.

Does a citrate-free nasal metoclopramide formulation avoid the patent?

It would have a strong noninfringement position against claim 1 because citrate is an express limitation. The formulation would still require review against other patents and against potential doctrine-of-equivalents arguments.

Is a 45 mg daily dose specifically protected?

Yes. Claim 16 separately recites a daily dose of approximately 45 mg, subject to all limitations inherited from claim 1.

Are benzalkonium chloride and sodium citrate required in every claimed product?

No. They are required only for the narrower dependent claims that recite them. Claim 1 requires citrate, but does not require benzalkonium chloride or sodium citrate specifically.

Can a 505(b)(2) product face this patent?

Yes. A 505(b)(2) applicant using or relying on the patented intranasal metoclopramide method could face patent-listing and infringement issues. The applicable certification and litigation consequences would depend on the FDA application, proposed labeling, listed patents, and patent-use codes.

References

United States Patent No. 12,194,008, claims 1-17.
Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355.
Patent Act, 35 U.S.C. §§ 271, 281, 283-285.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations [Orange Book].
U.S. Food and Drug Administration. (n.d.). Approved drug product labeling and regulatory information for metoclopramide.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Qol Medcl	GIMOTI	metoclopramide hydrochloride	SPRAY, METERED;NASAL	209388-001	Jun 19, 2020		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				NASAL ADMINISTRATION OF METOCLOPRAMIDE FOR TREATMENT OF DIABETIC GASTROPARESIS	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2780485	⤷ Start Trial
Canada	2984736	⤷ Start Trial
Canada	3155873	⤷ Start Trial
Canada	3224872	⤷ Start Trial
Denmark	2376075	⤷ Start Trial
European Patent Office	2376075	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 12,194,008

Which drugs does patent 12,194,008 protect, and when does it expire?

Summary for Patent: 12,194,008